Manufacturer
AstraZeneca
Contents
Rosuvastatin Ca
Indication
Reduction of elevated total cholesterol (total-C), LDL-C, ApoB, the total-C: HDL-C ratio & triglycerides & for increasing HDL-C, in hyperlipidemic & dyslipidemic conditions. Reduction of total mortality & risk of major CV events (CV death, stroke, MI, unstable angina or arterial revascularization) in adults w/ increased risk of atherosclerotic CV disease based on the presence of CV disease risk markers. Primary dysbetalipoproteinemia (type III hyperlipoproteinemia); primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia & severe non-familial hypercholesterolaemia); combined (mixed) dyslipidemia (type IIb); homozygous familial hypercholesterolaemia. Adjunctive therapy to diet to slow the progression of atherosclerosis in adults as part of a treatment strategy to lower total-C & LDL-C to target levels.
Instruction
May be taken with or without food.
Drug interaction
Warfarin, vit K antagonists, ciclosporin, gemfibrozil, niacin, fusidic acid, protease inhibitors, antacids (Al & Mg hydroxide), erythromycin, ketoconazole, spirinolactone, cimetidine, fibrates, atazanavir, simeprevir, clopidogrel, eltrombopag, darunavir, tipranavir, dronedarone, itraconazole, ezetimibe, fosamprenavir, aleglitazar, silymarin, rifampin, fluconazole, erythromycin, baicalin, OC, hormone replacement therapy.
Malaysia
